title: [Vaccination with genetically modified IL-2 secreting cells in a rat model of colonic carcinoma].
abstract: Genetically engineered tumor cells secreting immunostimulatory molecules could facilitate the obtention of a vaccination against tumor antigens. To test this approach, we transfected genes encoding for rat and mouse IL-2 into PROb cells. These cells originate from a dimethylhydrazine induced colon carcinoma of BD IX rats. We observed an inhibition of the in vivo tumor growth directly proportional to the IL-2 secretion. An immunohistochemical analysis revealed that the tumors were infiltrated by leucocytes expressing the IL-2 receptor, suggesting their activation within the tumor. A strong delay of tumor growth was observed in rats challenged with PROb cells after a previous rejection of IL-2 secreting cells. Yet two rats out of six were completely protected. This protection is specific since rejection of PROb-IL-2 does not confer protection towards the syngeneic glioma A15A5. In addition, we could show by depletion experiments that NK/LAK, CD8, and CD4 lymphocytes were involved in the rejection of cells secreting large amounts of IL-2. Macrophages appear to be involved in the rejection process too, but also in the induction of an immune memory. Vaccination experiments using irradiated PROb IL-2 cells were performed. Only a partial protection towards a challenge with parental PROb cells could be obtained, also depending on the amount of secreted IL-2: the best protection being obtained after vaccination with cells synthesizing a small amount of IL-2. However, this protection was not superior to that obtained by coinjection of irradiated PROb cells and BCG.
authors.affiliation: Inserm U419, Institut de Biologie, Nantes, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Patry
authors.forename: K
authors.initials: K
authors.lastname: Meflah
authors.forename: J
authors.initials: J
authors.lastname: Le Pendu
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D000818:Animals; D001500:BCG Vaccine / Q000276:immunology; D003110:Colonic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D004195:Disease Models, Animal; D005434:Flow Cytometry; D007150:Immunohistochemistry; D007167:Immunotherapy / Q000379:methods*; D007376:Interleukin-2 / Q000378:metabolism / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008212:Lymphocyte Depletion / Q000379:methods; D051379:Mice; D008819:Mice, Nude; D051381:Rats; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D001500:BCG Vaccine; D007376:Interleukin-2
vernacular_title: Vaccination par des cellules génétiquement modifiées sécrétant de l'IL-2 dans un modèle de carcinome colique de rat.